Xilio Therapeutics granted stock options for 19,865 shares to two new employees as part of their inducement plan.
Quiver AI Summary
Xilio Therapeutics, Inc. announced the granting of non-qualified stock options to purchase 19,865 shares of common stock to two new employees under its 2022 Inducement Stock Incentive Plan, effective September 1, 2026. The exercise price is set at $8.88 per share, matching the closing stock price on that date. The options will vest 25% on the first anniversary of employment, with the remaining 75% vesting in 36 monthly installments, contingent on continued service. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Xilio's commitment to developing masked immuno-oncology therapies aimed at improving cancer treatment outcomes with reduced systemic side effects.
Potential Positives
- The company successfully attracted new talent by granting non-qualified stock options to two new employees, indicating growth and potential for future development.
- The exercise price of the stock options is set at $8.88, reflecting the company's current market value, which may signify the company's stable stock performance.
- The grant under the 2022 Inducement Stock Incentive Plan demonstrates the company's commitment to incentivizing and retaining skilled employees, aligning employee interests with company performance.
Potential Negatives
- The grant of stock options to new employees may indicate a reliance on incentivizing talent due to potential difficulties in attracting skilled professionals in a competitive market.
- The disclosure of employee stock options could raise concerns among investors about the company’s cash flow and financial health, as it may signal plans for future dilution of stock.
FAQ
What stock options did Xilio Therapeutics grant to its new employees?
Xilio Therapeutics granted non-qualified stock options to purchase 19,865 shares at an exercise price of $8.88 per share.
When did Xilio Therapeutics grant these stock options?
The stock options were granted effective September 1, 2026.
What is the vesting schedule for the stock options?
The stock options vest 25% on the first anniversary of employment, with the remaining 75% vesting in 36 equal monthly installments.
What is the purpose of the inducement stock option grant?
This grant serves as an inducement for new employees to join Xilio Therapeutics, as permitted by Nasdaq Listing Rule 5635(c)(4).
What is the mission of Xilio Therapeutics?
Xilio Therapeutics aims to develop masked immuno-oncology therapies to improve cancer treatment outcomes while reducing systemic side effects.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$XLO Insider Trading Activity
$XLO insiders have traded $XLO stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $XLO stock by insiders over the last 6 months:
- JAMES SAMUEL SHANNON purchased 5,000 shares for an estimated $43,949
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$XLO Hedge Fund Activity
We have seen 14 institutional investors add shares of $XLO stock to their portfolio, and 23 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ORBIMED ADVISORS LLC added 592,300 shares (+inf%) to their portfolio in Q2 2026, for an estimated $5,674,234
- POINT72 ASSET MANAGEMENT, L.P. removed 285,714 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,402,854
- STEMPOINT CAPITAL LP removed 145,002 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,219,466
- CALIGAN PARTNERS LP removed 112,128 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $1,074,186
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 111,541 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,068,562
- EMPERY ASSET MANAGEMENT, LP removed 84,503 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $809,538
- STONEPINE CAPITAL MANAGEMENT, LLC added 55,143 shares (+611.4%) to their portfolio in Q1 2026, for an estimated $463,752
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective September 1, 2026, the company granted non-qualified stock options to purchase 19,865 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.
The stock options have an exercise price of $8.88 per share, which is equal to the closing price of the company’s common stock on September 1, 2026. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following commencement of employment, and the remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to continued service with the company or any of its subsidiaries through each applicable vesting date.
The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary masking technology to advance a pipeline of novel, masked I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn ( Xilio Therapeutics, Inc. ).
Investor Contact
Alex Lobo, Precision AQ
[email protected]
Media Contact
Josie Butler, 1AB
[email protected]
